MS Views and News Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, CLICK HERE - -

Please visit our MS learning channel on YouTube, which provides hundreds of MS videos presented by MS Experts across the USA, from many of our recorded education programs. Archived here: www.youtube.com/msviewsandnews -- Additionally, please visit our Social media platforms: Facebook, Twitter, and Instagram

Important Resources for the MS community are found on the left side of this blog.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~


Monday, April 29, 2019

New Genentech Data at the 2019 AAN Annual Meeting Showcase Breadth and Promise of Neuroscience Portfolio


Risdiplam data from Part 1 of pivotal FIREFISH study show infants with Type 1 spinal muscular atrophy achieve key motor milestones and improved survival after one year of treatment

New analyses in relapsing and primary progressive multiple sclerosis suggest that higher OCREVUS® (ocrelizumab) exposure and lower B-cell levels are important for control of disability progression
Satralizumab significantly reduces the risk of relapse in neuromyelitis optica spectrum disorder in pivotal SAkuraSky study

New data in Huntington’s disease support dose selection for Phase III trial and provide insight on mutant huntingtin protein (mHTT) reduction


SOUTH SAN FRANCISCO, Calif.--()--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new data for its approved and investigational medicines for the treatment of neurological conditions will be presented at the 71st American Academy of Neurology (AAN) Annual Meeting from May 4-10 in Philadelphia, PA. Presentations include data from a pivotal study for risdiplam in spinal muscular atrophy (SMA), which has the potential to become the first oral treatment for this community. New research for OCREVUS® (ocrelizumab) in relapsing and primary progressive multiple sclerosis shows that its effect on reducing the risk of disability progression is associated with higher exposure and lower B-cell levels. Additional OCREVUS data demonstrate the importance of earlier treatment. New data for investigational medicines in neuromyelitis optica spectrum disorder (NMOSD), Huntington’s disease (HD), Alzheimer’s disease (AD) and Duchenne muscular dystrophy (DMD) will also be shared.
READ MORE


::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
                   
Article Provided by:  #MSViewsandNews
:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::